Navigation Links
AIDS Vaccine Failures Highlight Need to Focus on Lifesaving Treatment, Says AHF
Date:11/15/2007

As Vaccine Efforts Stumble, Millions Remain Without AIDS Treatment

Worldwide

LOS ANGELES, Nov. 15 /PRNewswire-USNewswire/ -- For the second time in two weeks, clinical researchers working to develop an AIDS vaccine have announced that their efforts have stumbled or, in the case of Merck -- outright failed -- after Merck's AIDS vaccine trial was halted last week when its vaccine was suspected of actually making some study participants more susceptible to contracting HIV. These latest shortcomings in the increasingly elusive search for a safe and effective AIDS vaccine underscore the need to focus on promoting HIV prevention and scaling up the delivery of lifesaving antiretroviral treatment (ART), both proven and existing strategies, to help keep people around the world from becoming infected, or for those already living with HIV/AIDS, alive and well, said AIDS Healthcare Foundation (AHF).

Earlier today, Reuters reported that " ... another experimental AIDS vaccine may damage the immune system by exhausting key cells ... a finding that may further cloud the field of HIV vaccines." Reuters noted that the researchers, who published their findings in the 'Journal of Clinical Investigation' said that, " ... vaccines using the viruses should not be tested on people until more studies are done," and that, " ... In mice, the adeno-associated virus, or AAV vaccines, directly interfered with immune cells called CD8 T-cells ... the 'killer' T-cells that a vaccine is supposed to muster to fight HIV."

"Development of a safe and effective AIDS vaccine is a clearly a noble and worthy goal; however, the sad truth remains that more than 40 million people worldwide are living with HIV/AIDS today, yet barely two million of them have access to lifesaving antiretroviral AIDS treatments," said Michael Weinstein, AIDS Healthcare Foundation President. "Treatments that actually do work and help keep those fortunate enough to have access to them alive and well. Treatments, which also have also been around, and continually improved, for over a decade. These recent failures in vaccine development underscore just how tenuous the quest for an AIDS vaccine remains, and reminds us of what effective, but underused tools, including antiretroviral treatment, we already have available to us today. While we long for the day when there is an effective preventive AIDS vaccine, we also call for a reevaluation of the distribution of limited government resources in the battle against AIDS, and renew our call for a greatly stepped-up worldwide commitment to bringing antiretroviral treatment to many, many more of those 38 million people still in need."

About AHF

AIDS Healthcare Foundation (AHF) is the US' largest non-profit HIV/AIDS healthcare, research, prevention and education provider. AHF currently provides medical care and/or services to more than 61,000 individuals in 18 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at http://www.aidshealth.org


'/>"/>
SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Footwear Foundation, the national charitable foundation serving the footwear industry, has broken all ... representing more than 130 companies across 23 states during the months of April ...
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite ... a light breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers ... and 1-mile walk were held to increase awareness about Lyme disease and to ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology: